MALAKOFF, France–(BUSINESS WIRE)–Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, the first platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, announced top-line results from its VEINRESET pivotal U.S. clinical trial today. Primary endpoint met: Occlusion rate at 12 months was 96.8%, confirming strong efficacy. Excellent safety profile: No serious or unanticipated adverse events, only one mild